IOncology

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. In a recent late-breaking abstract (LBA) report, Professor Samuel R. Denmeade from Johns Hopkins University School of Medicine shared the specific results of the TRANSFORMER trial. This randomized trial targeted abiraterone-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, aiming to identify blood biomarkers. "Oncology Frontier" had the opportunity to interview Professor Samuel R. Denmeade to highlight the potential benefits and future directions of bipolar androgen therapy (BAT), a new treatment approach.

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage breast cancer, CDK4/6 inhibitors have also shown positive results and have been approved for indications. The 2024 ASCO conference presented multiple advancements in the adjuvant treatment of HR+/HER2- early-stage breast cancer with CDK4/6 inhibitors. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum, Oncology Frontier invited Professor Hong Hu from Shenzhen People's Hospital, and Professor Yuntao Wei from Liaoning Cancer Hospital & Institute to elaborate on and discuss the research progress of CDK4/6 inhibitors in adjuvant therapy for HR+ early-stage breast cancer.

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Bin Hua from Beijing Hospital and Professor Juliang Zhang  from Xijing Hospital of Air Force Medical University  discuss these latest research advancements in depth.

With continuous advancements in medical research, treatment strategies for triple-negative breast cancer (TNBC) are also evolving. From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was held in the romantic city of Dalian. Multiple significant studies on TNBC treatment were highlighted at ASCO, including the application of platinum-based therapies, new adjuvant treatment models, intensified adjuvant treatments, and the use of immunotherapy and ADCs in (neo)adjuvant settings. Oncology Frontier invited Professor Sifeng Tao from The Second Affiliated Hospital Zhejiang University School of Medicine and Professor Hui Liu fro

Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Dalian Xinghai Medical Forum, Oncology Frontier invited Professor Baoliang Guo from The Second Affiliated Hospital of Harbin Medical University, Professor Guiying Xu from Jilin Cancer Hospital to discuss the application of ctDNA monitoring in breast cancer.

In recent years, the rapid development of immunotherapy and targeted therapy has continuously updated the treatment strategies for metastatic breast cancer (MBC) patients. PARP inhibitors and immune checkpoint inhibitors, developed based on the concept of synthetic lethality, have become important treatment options for HER2- MBC patients, yet there remains a significant unmet need for treatment. Recently, at the ASCO 2024 conference, a collaborative team led by Professors Zhen Hu , Jian Zhang, and Yun Liu from Fudan University Shanghai Cancer Center shared the results of the Phase II CHANGEABLE study. This study revealed new hope for the combination of the PARP inhibitor niraparib and the PD-1 monoclonal antibody HX008 in MBC patients with germline DDR gene mutations. At ASCO 2024, Oncology Frontier interviewed Professor Jian Zhang to discuss the background, results, and significance of this study. The key insights are summarized below:

Soft tissue sarcoma (STS) is a rare and highly heterogeneous malignant tumor, and exploring treatment strategies for it has been a key focus in oncology research. In recent years, with the deepening of molecular biology and immunology research, clinical understanding and treatment methods for these diseases have continually advanced. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several key studies on soft tissue sarcoma released the latest clinical data. "Oncology Frontier" invited Professor Lili Mao from Peking Cancer Hospital to provide an in-depth analysis of these studies, summarizing the current progress in STS treatment research and discussing the clinical significance and future application prospects of these findings.

From June 14-16, 2024, the 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum was grandly held, bringing together cutting-edge developments from home and abroad. At the previous ASCO conference, the results of the I-SPY 2.2 study were released, providing new insights into optimizing neoadjuvant treatment plans for breast cancer, exploring the application of immune checkpoint inhibitors combined with antibody-drug conjugates (ADCs), and investigating step-up and step-down treatment strategies. At the Xinghai Forum, Oncology Frontier invited Professor Shu Wang from Peking University People's Hospital, Professor Zhigang Yu from Qilu Hospital of Shandong University, Professor Haibo Wang from The Affiliated Hospital of Qingdao University, and Professor Guangyu Liu from Fudan University Shanghai Cancer Center to discuss the highlights of the I-SPY 2.2 study and its reference value for clinical practice.

mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient's immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown promising efficacy in clinical trials. In the phase II KEYNOTE-942 study, mRNA-4157 combined with pembrolizumab extended relapse-free survival (RFS) for high-risk melanoma patients compared to pembrolizumab alone. At this year's ASCO meeting, the study presented updated 3-year follow-up data. Oncology Frontier has compiled and summarized the findings for our readers.